How to Test for Donor-Specific Antibodies (DSA)
DSA testing is performed using solid-phase single antigen bead (SAB) assays with Luminex technology, which detect anti-HLA antibodies in recipient serum and measure their intensity as mean fluorescence intensity (MFI) values. 1
Core Testing Methodology
Primary Assay Platform
- Single Antigen Bead (SAB) assays are the gold standard for DSA detection
- These use beads coated with recombinant HLA antigens analyzed via Luminex multiplex technology
- Results are reported as MFI (mean fluorescence intensity) values, with higher MFI indicating stronger antibody binding 2, 3
Essential Pre-Testing Requirements
High-resolution HLA genotyping (2-field typing) of both donor and recipient is strongly recommended to accurately identify which detected anti-HLA antibodies are truly donor-specific 1. This is a Grade 1A recommendation for kidney transplants and Grade 1B for heart and lung transplants.
Sample Collection and Timing
The 2023 STAR consensus guidelines provide organ-specific timing recommendations 1:
For Kidney Transplant Recipients:
- Test sample used at time of transplant (Grade 1B)
- With allograft dysfunction (Grade 1B)
- In high-risk situations: after immunosuppression minimization, CNI avoidance protocols, or nonadherence (Grade 1A)
- Routine surveillance without clinical events (Grade 1C)
For Heart Transplant Recipients:
- Test sample at time of transplant (Grade 1B)
- With allograft dysfunction (Grade 1B)
- Routine surveillance without clinical events (Grade 2B)
- Typical protocol: every 2 weeks for 1 month, monthly for 4 months, bimonthly for 6 months, then every 6-12 months 1
For Lung and Liver Transplant Recipients:
- Similar timing but with lower evidence grades (Grade 1B-2C depending on indication)
Interpretation of Results
MFI Threshold Considerations
There is no universal MFI cutoff, but common clinical thresholds include:
- MFI >1000: Generally considered positive for DSA presence 1
- MFI >3000: Associated with increased acute rejection risk 4
- MFI >7000: Indicates antibodies exceeding linear range of assay, may warrant dilution testing 2
- MFI >15,000: Strongly correlates with complement-fixing capacity 2
Critical caveat: Even low-MFI DSAs (<1000) can cause anamnestic antibody-mediated rejection, particularly with HLA class II antibodies 5. Do not dismiss low-level DSAs as clinically irrelevant.
Ancillary Testing Methods
Complement-Binding Assays
C1q and C3d binding assays identify DSAs capable of activating complement, which are associated with worse outcomes 1, 2:
- C1q-positive DSAs typically have MFI >15,000 in standard assays
- Complement binding correlates most strongly with total IgG concentration, not specific subclasses
- Grade 2C recommendation for use in characterizing DSAs
Dilution Studies
- 1:16 dilution testing helps identify high-titer antibodies
- DSAs detectable at 1:16 dilution typically have MFI >7000 in neat sera 2
- Useful for distinguishing clinically significant from borderline DSAs
IgG Subclass Testing
- Can identify IgG1, IgG2, IgG3, and IgG4 subclasses
- Grade 2C-2D recommendation across organ types
- Limited evidence for routine clinical utility 1
Common Pitfalls to Avoid
Failing to perform high-resolution typing: Without 2-field HLA typing, you cannot accurately determine if detected antibodies are truly donor-specific 1
Ignoring low-MFI DSAs: Values <1000 MFI can still cause rejection, especially in sensitized patients 5
Not testing archived pre-transplant sera: Retrospective testing of pre-transplant samples is essential when post-transplant DSAs are detected 5
Relying solely on flow cytometry crossmatch: Cell-based assays are less sensitive than SAB assays; negative FCXM does not exclude clinically relevant DSAs 4
Single timepoint testing: Serial DSA monitoring is recommended (Grade 1C for kidney, 1D for heart) to assess kinetics and persistence 1
Integration with Clinical Management
DSA testing should never be interpreted in isolation. The 2023 STAR guidelines emphasize integrating DSA results with:
- Allograft function parameters
- Histologic findings from biopsy
- Clinical presentation
- Timing (preformed vs. de novo DSA) 1
When DSAs are detected with allograft dysfunction, proceed to allograft biopsy (Grade 1C for kidney and heart, Grade 2D for lung, Grade 2C for liver) 1.